Stroke is a leading cause of disability with many patients suffering chronic motor function impairments that affect their day-to-day activities. The goal of this proposal is to provide a first assessment of the feasibility and efficacy of an innovative non-invasive brain stimulation system, kTMP, in the treatment of motor impairment following stroke.
The goal of this study is to test the feasibility of a novel first-in-class non-invasive approach to enhance motor function in stroke patients. This study has a crossover design comparing low-frequency (3 Hz) versus beta-frequency (13-30 Hz) amplitude modulation in kTMP on upper extremity kinematics in chronic stroke patients. The kilohertz Transcranial Magnetic Perturbation (kTMP) device allows the investigators to target frequency-specific neural activity non-invasively - with no patient discomfort - at and beyond stimulation intensities associated with enhanced recovery from stroke (up to 8 V/m), something that is not possible to achieve with existing NIBS methods. The trial also aims to assess the short-term effects of kTMP on reach-to-grasp kinematics. kTMP stimulation is targeted to the motor hotspot for eliciting motor evoked potentials (MEPs) within motor cortex to evaluate short term changes in motor performance.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
7
A new non-invasive brain stimulation tool
Magnetic Tides Inc.
Berkeley, California, United States
Reach-to-grasp (Range of Motion)
Defined as the standard deviation of the joint angle time series for a given trial. The average will be computed over a set of 15 trials.
Time frame: 3 weeks
Fugl- Meyer Assessment (Upper Extremity)
A comprehensive clinical examination that has been widely used to evaluate stroke-related motor impairment. It is graded from 0 (hemiplegia) to 66 for the Upper extremity. Higher scores signifies better motor control, and hence a better outcome.
Time frame: 3 weeks
Modified Ashworth Scale (MAS)
Clinical tool for measuring muscle spasticity and increased muscle tone. The MAS is a 6-point scale (0, 1, 1+, 2, 3, 4) measuring spasticity from no increase in tone to rigid limbs. Higher scores indicate greater spasticity, increased muscle tone, and greater upper limb rigidity, reflecting poorer outcomes.
Time frame: 3-weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.